VTIX — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-19

• We believe Virtuix is a leader in AI-driven, full-body simulation for immersive entertainment, defense training, and enterprise applications. We pioneer movement in AI-generated worlds, whether imaginary or real, through the development of omni-directional treadmills that let users walk and run in 3…

• Since inception, we have operated at a loss, with revenues of $767,300 and $1,032,136 for the three months ended June 30, 2026 and 2025, respectively. Our net losses were $(7,170,566) and $(2,307,155) for the three months ended June 30, 2026 and 2025, respectively. We anticipate continued operating …

• ● Scaling Omni One consumer sales through increased marketing and increased adoption as part of the Made for Meta program.

• Sales for the three months ended June 30, 2026, were $767,300, a 26% decrease from sales of $1,032,136 for the three months ended June 30, 2025. This decrease is primarily attributable to the fulfillment of the final batch of the large backlog of Omni One orders accumulated since the start of the pr…

• Cost of goods sold in the three months ended June 30, 2026 was $540,142, a decrease of $315,917 from cost of goods sold of $856,059 in the three months ended June 30, 2025. The decrease was primarily attributable to lower revenues during the current period compared to the prior period that included …

Text removed vs the prior filing · source: 10-Q · 2026-03-06

• Virtuix pioneers movement in AI-generated worlds, whether imaginary or real, through the development of omni-directional treadmills that enable natural locomotion within VR games, digital twins, and other applications. Since our founding in 2013, we have introduced three generations of products to m…

• ●Scaling Omni One consumer sales through increased marketing.

• Comparison of the Nine Months Ended December 31, 2025 and 2024

• Net sales for the nine months ended December 31, 2025, were $2,980,765, a 41% increase from sales of $2,110,889 for the nine months ended December 31, 2024. This increase is primarily attributable to new sales of Omni One, including resulting from a strong 2025 holiday season, and the fulfillment of…

• Omni Pro units and accessories, net of discounts $154,958 $127,412

Text added vs the prior filing · source: 10-Q · 2026-08-19

• Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of June 30, 2026. Based on this evaluation, our Chief Executi…

• During the preparation of our condensed consolidated financial statements for the three months ended June 30, 2026, management identified a material weakness in internal control over financial reporting related to the accounting for complex financing transactions. Specifically, the Company did not m…

• Other than the identification of the material weakness described above, which reflected a deficiency in controls that existed as of March 31, 2026 and continued through June 30, 2026 and therefore did not constitute a change in ICFR during the quarter, there were no changes in our internal control o…

Text removed vs the prior filing · source: 10-Q · 2026-03-06

• Under the supervision and with the participation of our Management, including our Certifying Officers, we carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on …

• We do not expect that our disclosure controls and procedures will prevent all errors and all instances of fraud. Disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and proc…

• There was no change in our internal control over financial reporting that occurred during the fiscal quarter covered by this Report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Text added vs the prior filing · source: 10-Q · 2026-08-19

• In February 2024, the Company was named a co-defendant and served a citation by a customer related to alleged injuries obtained when attempting to use the Omni Arena attraction at an entertainment venue. The Company’s attorneys, retained by the Company’s insurance provider, filed a general denial an…

• From time to time, we may be party to litigation arising in the ordinary course of business. As of June 30, 2026, we are not subject to any material legal proceedings nor, to the best of our knowledge, are any material legal proceedings pending or threatened against us.

Text removed vs the prior filing · source: 10-Q · 2026-03-06

• From time to time, we may be party to litigation arising in the ordinary course of business. As of December 31, 2025, we are not subject to any material legal proceedings nor, to the best of our knowledge, are any material legal proceedings pending or threatened against us.

Text added vs the prior filing · source: 10-Q · 2026-08-19

• We have identified a material weakness in our internal control over financial reporting related to the accounting for complex financing transactions, and our failure to remediate this material weakness or otherwise maintain effective internal controls could adversely affect our financial reporting a…

• During the preparation of our condensed consolidated financial statements for the three months ended June 30, 2026, management identified a material weakness in our internal control over financial reporting related to the accounting for complex financing transactions. Specifically, the Company did n…

• This material weakness existed as of March 31, 2026 and continued to exist as of June 30, 2026, and resulted in errors in the accounting for certain financing arrangements that required revisions to previously reported financial information.

• We have begun implementing remediation measures designed to strengthen our controls over complex and non-routine financing transactions, including enhanced procedures for identifying transactions requiring technical accounting analysis, documented review of significant contractual terms and embedded…

• Until this material weakness is remediated, there is a reasonable possibility that a material misstatement of our annual or interim financial statements may not be prevented or detected on a timely basis. If we are unable to remediate this material weakness or otherwise maintain effective internal c…

Text added vs the prior filing · source: 10-Q · 2026-08-19

• Our Section 16 officers and directors, as defined in Rule 16a-1(f) of the Exchange Act, may from time to time enter into plans for the purchase or sale of our common stock that are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act. During the quarter ended …

• On May 6, 2026, Jan Goetgeluk, our Chief Executive Officer, completed all sales contemplated under his Rule 10b5-1 trading arrangement, which was adopted on January 6, 2026 for up to 500,000 shares of our Class A common stock. As a result, Mr. Goetgeluk’s 10b5-1 trading arrangement terminated on May…

• ●On June 30, 2026, Ugo de Charette, a member of our Board of Directors, adopted a new written trading plan. The plan’s maximum duration is until March 29, 2027 and the first trade will not occur until September 29, 2026, at the earliest. The trading plan is intended to permit Mr. de Charette to sell…

• Other than as set forth above, no other director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of Regulation S-K.

Text removed vs the prior filing · source: 10-Q · 2026-03-06

• During the three months ended December 31, 2025, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of Regulation S-K.